IQV vs NIQ
IQV: IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2 billion de-identified patient records. NIQ: NIQ is a consumer intelligence and market research platform powered by its Connect data engine, serving CPG and adjacent verticals with integrated insights from Nielsen's legacy research business and the 2023 GfK combination.
Side-by-side fundamentals
| Metric | IQV | NIQ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $198.52 | $10.63 | |
| Market cap as of 2026-07-23 | $33.2B | $3.1B | |
| P/E as of 2026-07-23 | 23.98 | n/a | |
| PEG as of 2026-07-23 | 2.51 | n/a | |
| Net margin as of 2026-07-23 | +8.3% | -7.8% | IQV higher |
| Gross margin as of 2026-07-23 | +33.0% | +55.7% | NIQ higher |
| Operating margin as of 2026-07-23 | +13.2% | +1.4% | IQV higher |
| ROE as of 2026-07-23 | +22.5% | -43.9% | IQV higher |
| ROA as of 2026-07-23 | +4.7% | -4.9% | IQV higher |
| Debt / equity as of 2026-07-23 | 2.55 | 3.89 | IQV lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.3% | +44.0% | NIQ higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +12.1% | NIQ higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 1.20 | -0.04 | |
| 1-year return as of 2026-07-22 close | +26.8% | -35.5% | IQV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.